ccm-20211231x20f.htm

Exhibit 8.1

List of Subsidiaries and Consolidated Affiliate Entities

Outside PRC

Ascendium Group Limited (British Virgin Islands)

Cyber Medical Network Limited (Hong Kong)

Medstar Overseas Limited (British Virgin Islands)

Our Medical Services Ltd. (British Virgin Islands)

King Cheers Holdings Limited (Hong Kong)

Concord Hospital Management Group Limited (Hong Kong)

Global Medical Imaging (Hongkong) Limited (Hong Kong)

CCM (Hong Kong) Medical Investments Limited (Hong Kong)

Concord Medical Investment Management Limited (British Virgin Islands)

Concord Healthcare Singapore PTE. Ltd. (Singapore)

China Medical Services Holdings Limited (Hong Kong)

US Proton Therapy Holdings Limited (British Virgin Islands)

US Proton Therapy Holdings Limited (Delaware, United States)

Oriental Light Group Limited (British Virgin Islands)

PRC

Concord Healthcare Group Co., Ltd.

Shenzhen Aohua Medical Technology Development Co., Ltd.

Shanghai Taifeng Medical Technology Ltd.

Shanghai Meizhong Jaihe General Practice Center

Medstar (Shanghai) Financial Leasing Co., Ltd.

Tianjin Concord Medical Technology Limited

Medstar (Guangzhou) Medical Technology Services Ltd.

Medstar (Tianjin) Medical Technology Services Ltd.

Jiaxue (Shanghai) Medical Technology Services Ltd.

Beijing Century Friendship Science & Technology Development Co., Ltd.

Beijing Proton Medical Center Co., Ltd

Shanghai Concord Cancer Center

Shanghai Meizhong Jiahe Medical Image Diagnosis Limited

Shanghai Meizhong Jiahe Cancer Center

Shenzhen Concord Medical Investments Limited

Datong Meizhong Jiahe Cancer Center

Datong Meizhong Jiahe Traditional Chinese Medical Center

Shanghai Taizhi Medical Technology Services Ltd.

Beijing Yundu Internet Technology Co., Ltd.

Guangzhou Concord Cancer Center

Ningbo Jiahe Hospital Management Ltd.

Yinchuan Meizhong Jiahe Internet Hospital Ltd.

Guangzhou Concord Hospital Management Ltd.

Guangzhou Concord Medical Center Ltd.

Guangzhou Concord Medical Sci-Tech Innovation Center Ltd.

Exhibit 12.1

Certification by the Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Jianyu Yang, certify that:

1.I have reviewed this annual report on Form 20-F of Concord Medical Services Holdings Limited;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

4.The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

5.The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

April 29, 2022

	By:	/s/ Jianyu Yang
	Name:	Jianyu Yang
	Title:	Chief Executive Officer

Exhibit 12.2

Certification by the Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Yaw Kong Yap, certify that:

I have reviewed this annual report on Form 20-F of Concord Medical Services Holdings Limited;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;

The company’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and

The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.


April 29, 2022

	By:	/s/ Yaw Kong Yap
	Name:	Yaw Kong Yap
	Title:	Chief Financial Officer

Exhibit 13.1

Certification by the Principal Executive Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Annual Report of Concord Medical Services Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jianyu Yang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

April 29, 2022

		By:	/s/ Jianyu Yang
		Name:	Jianyu Yang
		Title:	Chief Executive Officer

Exhibit 13.2

Certification by the Principal Financial Officer

Pursuant to Section 906 of the Sarbanes - Oxley Act of 2002

In connection with the Annual Report of Concord Medical Services Holdings Limited (the “Company”) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yaw Kong Yap, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

April 29, 2022


		By:	/s/ Yaw Kong Yap
		Name:	Yaw Kong Yap
		Title:	Chief Financial Officer

Exhibit 15.1

CONSENT OF Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-222559) pertaining to the 2008 Share Incentive Plan of Concord Medical Services Holdings Limited of our reports dated April 29, 2022, with respect to the consolidated financial statements of Concord Medical Services Holdings Limited included in this Annual Report (Form 20-F) for the year ended December 31, 2020, filed with the Securities and Exchange Commission.

/s/ Shandong Haoxin Certified Public Accountants Co., Ltd.
Shandong Haoxin Certified Public Accountants Co., Ltd.
Weifang, the People’s Republic of China

April 29, 2022